Table 1.
Baseline patient characteristics of the full analysis set (FAS) population
| Characteristics | NEPA (N = 412) |
APR + GRAN (N = 416) |
Total (N = 828) |
|---|---|---|---|
| Age, mean (SD), years | 54.5 (9.59) | 54.5 (10.24) | 54.5 (9.91) |
| Sex | |||
| Male | 291 (70.6%) | 297 (71.4%) | 588 (71.0%) |
| Female | 121 (29.4%) | 119 (28.6%) | 240 (29.0%) |
| Asian ethnicity | 412 (100.0%) | 416 (100.0%) | 828 (100.0%) |
| ECOG PS score | |||
| 0 | 175 (42.5%) | 171 (41.1%) | 346 (41.8%) |
| 1 | 230 (55.8%) | 236 (56.7%) | 466 (56.3%) |
| 2 | 7 (1.7%) | 9 (2.2%) | 16 (1.9%) |
| Cancer type | |||
| Lung cancer | 275 (66.7%) | 267 (64.2%) | 542 (65.5%) |
| Not lung cancer | 137 (33.3%) | 149 (35.8%) | 286 (34.5%) |
| Metastatic disease status | |||
| Yes | 176 (42.7%) | 136 (32.7%) | 312 (37.7%) |
| No | 236 (57.3%) | 280 (67.3%) | 516 (62.3%) |
APR, aprepitant; ECOG, Eastern Cooperative Oncology Group; GRAN, granisetron; NEPA, netupitant and palonosetron; PS, performance status